Sanofi Gross Profit 2010-2024 | SNY
Sanofi annual/quarterly gross profit history and growth rate from 2010 to 2024. Gross profit can be defined as the profit a company makes after deducting the variable costs directly associated with making and selling its products or providing its services.
- Sanofi gross profit for the quarter ending September 30, 2024 was $11.075B, a 14.89% increase year-over-year.
- Sanofi gross profit for the twelve months ending September 30, 2024 was $36.774B, a 7.92% increase year-over-year.
- Sanofi annual gross profit for 2023 was $34.859B, a 4.39% increase from 2022.
- Sanofi annual gross profit for 2022 was $33.393B, a 4.85% increase from 2021.
- Sanofi annual gross profit for 2021 was $31.849B, a 10.59% increase from 2020.
Sanofi Annual Gross Profit
(Millions of US $) |
| 2023 |
$34,859 |
| 2022 |
$33,393 |
| 2021 |
$31,849 |
| 2020 |
$28,800 |
| 2019 |
$28,734 |
| 2018 |
$28,630 |
| 2017 |
$27,797 |
| 2016 |
$26,565 |
| 2015 |
$26,585 |
| 2014 |
$30,680 |
| 2013 |
$29,642 |
| 2012 |
$31,945 |
| 2011 |
$33,644 |
| 2010 |
$30,964 |
| 2009 |
$31,893 |
Sanofi Quarterly Gross Profit
(Millions of US $) |
| 2024-09-30 |
$11,075 |
| 2024-06-30 |
$8,583 |
| 2024-03-31 |
$8,337 |
| 2023-12-31 |
$8,779 |
| 2023-09-30 |
$9,640 |
| 2023-06-30 |
$8,084 |
| 2023-03-31 |
$8,355 |
| 2022-12-31 |
$7,996 |
| 2022-09-30 |
$9,374 |
| 2022-06-30 |
$7,973 |
| 2022-03-31 |
$8,050 |
| 2021-09-30 |
$8,951 |
| 2021-06-30 |
|
| 2021-03-31 |
$7,477 |
| 2020-09-30 |
$7,835 |
| 2020-03-31 |
$7,117 |
| 2019-09-30 |
$7,547 |
| 2019-03-31 |
$6,923 |
| 2018-03-31 |
$6,860 |
| 2017-12-31 |
$6,943 |
| 2017-09-30 |
$7,686 |
| 2017-06-30 |
$6,654 |
| 2017-03-31 |
$6,514 |
| 2016-12-31 |
$6,708 |
| 2016-09-30 |
$7,275 |
| 2016-06-30 |
$6,535 |
| 2016-03-31 |
$6,047 |
| 2015-09-30 |
$7,434 |
| 2015-06-30 |
$7,216 |
| 2014-06-30 |
$7,597 |
| 2013-06-30 |
$7,066 |
| 2012-06-30 |
$8,204 |
| 2012-03-31 |
$7,803 |
| 2011-12-31 |
$7,948 |
| 2011-09-30 |
$7,988 |
| 2011-06-30 |
$7,960 |
| 2011-03-31 |
$8,191 |
| 2010-12-31 |
$6,923 |
| 2010-09-30 |
$7,826 |
| 2010-06-30 |
$8,001 |
| 2010-03-31 |
$6,934 |
| 2009-12-31 |
$7,000 |
| 2009-09-30 |
$8,023 |
| 2009-06-30 |
$8,059 |
| 2009-03-31 |
$6,720 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$118.770B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
